These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1012 related items for PubMed ID: 30796708

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical and Prognostic Value of PET/CT Imaging with Combination of 68Ga-DOTATATE and 18F-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M.
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [Abstract] [Full Text] [Related]

  • 3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S.
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [Abstract] [Full Text] [Related]

  • 4. Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Metser U, Nunez JE, Chan D, Kulanthaivelu R, Murad V, Santiago AT, Singh S.
    J Nucl Med; 2024 Oct 01; 65(10):1591-1596. PubMed ID: 39266292
    [Abstract] [Full Text] [Related]

  • 5. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and Multimodality Anatomic Imaging in Metastatic Neuroendocrine Tumors of Unknown Primary in a PRRT Workup Setting.
    Sampathirao N, Basu S.
    J Nucl Med Technol; 2017 Mar 01; 45(1):34-41. PubMed ID: 28154019
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined Quantification of 18F-FDG and 68Ga-DOTATATE PET/CT for Prognosis in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.
    Lee H, Nakamoto R, Moore SE, Pantel AR, Eads JR, Aparici CM, Pryma DA.
    Acad Radiol; 2022 Sep 01; 29(9):1308-1316. PubMed ID: 34836776
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
    Thuillier P, Maajem M, Schick U, Blanc-Beguin F, Hennebicq S, Metges JP, Salaun PY, Kerlan V, Bourhis D, Abgral R.
    Clin Nucl Med; 2021 Feb 01; 46(2):111-118. PubMed ID: 33234927
    [Abstract] [Full Text] [Related]

  • 12. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
    Crown A, Rocha FG, Raghu P, Lin B, Funk G, Alseidi A, Hubka M, Rosales J, Lee M, Kennecke H.
    J Surg Oncol; 2020 Mar 01; 121(3):480-485. PubMed ID: 31853990
    [Abstract] [Full Text] [Related]

  • 13. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Yu J, Cao F, Zhao X, Xie Q, Lu M, Li J, Yang Z, Sun Y.
    Neuroendocrinology; 2022 Mar 01; 112(4):358-369. PubMed ID: 34077939
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E, Alshammari A, Michopoulou S, Skoura E, Naik K, Maragkoudakis E, Mohmaduvesh M, Al-Harbi M, Belda M, Caplin ME, Toumpanakis C, Bomanji J.
    J Nucl Med; 2017 Jan 01; 58(1):91-96. PubMed ID: 27516446
    [Abstract] [Full Text] [Related]

  • 15. Sensitivity Comparison of 68Ga-OPS202 and 68Ga-DOTATOC PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase II Imaging Study.
    Nicolas GP, Schreiter N, Kaul F, Uiters J, Bouterfa H, Kaufmann J, Erlanger TE, Cathomas R, Christ E, Fani M, Wild D.
    J Nucl Med; 2018 Jun 01; 59(6):915-921. PubMed ID: 29191855
    [Abstract] [Full Text] [Related]

  • 16. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sevilla I, Lopez C, Alonso T, Garcia-Carbonero R.
    Oncologist; 2018 Apr 01; 23(4):422-432. PubMed ID: 29330208
    [Abstract] [Full Text] [Related]

  • 17. Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
    Labora A, Shimizu T, Moore A, Premji A, Armstrong WR, Chen KY, Link J, Chan CS, Allen-Auerbach MS, Donahue TR.
    Ann Surg Oncol; 2024 Oct 01; 31(10):6875-6882. PubMed ID: 38909116
    [Abstract] [Full Text] [Related]

  • 18. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
    Sharma A, Das CJ, Makharia GK, Arora G, Kumar R.
    Clin Nucl Med; 2020 Nov 01; 45(11):848-853. PubMed ID: 32657875
    [Abstract] [Full Text] [Related]

  • 19. Feasibility of Radio-Guided Surgery with ⁶⁸Gallium-DOTATATE in Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumors.
    Sadowski SM, Millo C, Neychev V, Aufforth R, Keutgen X, Glanville J, Alimchandani M, Nilubol N, Herscovitch P, Quezado M, Kebebew E.
    Ann Surg Oncol; 2015 Dec 01; 22 Suppl 3(Suppl 3):S676-82. PubMed ID: 26350374
    [Abstract] [Full Text] [Related]

  • 20. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms.
    Karls S, Gold R, Kravets S, Wang Y, Cheng S, Perez K, Chan J, Jacene H.
    Ann Nucl Med; 2021 Sep 01; 35(9):1066-1077. PubMed ID: 34146243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.